China's Tsingke Biotechnology secures $57m in Series B round

China's Tsingke Biotechnology secures $57m in Series B round

Photo by RephiLe on Unsplash

Chinese gene synthesis firm Tsingke Biotechnology has bagged 400 million yuan ($57.2 million) in a Series B round led by Fortune Capital as well as Henan CICC Huirong Fund Management, a fund jointly set up by Henan Investment Group and CICC Capital. 

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter